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Abstract
Background: MiRNAs regulate multiple genes at the post-transcriptional level and therefore play an important role
in many biological processes. It has been suggested that miRNA exported outside the cells contribute to inter-
cellular communication. Consequently, circulating miRNAs are of particular interest and are promising biomarkers
for many diseases. The number of miRNAs annotated in the horse genome is much lower compared to model
organisms like human and mouse. We therefore aimed to identify novel equine miRNAs for tissue types and breed
in serum.
Results: We analysed 71 small RNA-seq libraries derived from nine tissues (gluteus medius, platysma, masseter
muscle, heart, liver, cartilage, bone, total blood and serum) using miRDeep2 and miRdentify tools. Known miRNAs
represented between 2.3 and 62.9 % of the reads in 71 libraries. A total of 683 novel miRNAs were identified. Breed
and tissue type affected the number of miRNAs detected and interestingly, affected its average intensity. A total of
50 miRNAs in serum proved to be potential biomarkers to differentiate specific breed types, of which miR-122, miR-200,
miR-483 were over-expressed and miR-328 was under-expressed in ponies compared to Warmbloods. The different
miRNAs profiles, as well as the differences in their expression levels provide a foundation for more hypotheses based
on the novel miRNAs discovered.
Conclusions: We identified 683 novel equine miRNAs expressed in seven solid tissues, blood and serum. Additionally,
our approach evidenced that such data supported identification of specific miRNAs as markers of functions related to
breeds or disease tissues.
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Background
MiRNAs are endogenous ~22-nt noncoding RNAs that
impact molecular mechanisms through the regulation of
mRNA post-transcription and/or translation [1]. Regula-
tion of gene expression by miRNAs requires direct inter-
action between the mature miRNA and, most often, the
3’ untranslated region of target mRNAs. Changes in the
expression pattern of a miRNA can expose novel sets of
genes to its regulatory influence [2]. The great current
interest in miRNAs reflects their implication in diverse
developmental processes and in the pathogenesis of can-
cer, cardiac, immune-related, pulmonary and other dis-
eases [3]. Moreover, they are more stable, even outside a
cell, compared to other long RNA molecules as they are
either packed into microparticles, or protected by associ-
ated RNA-binding proteins (Argonaute 2) or lipoprotein
complexes, which protect them from the RNAses activ-
ity [4]. Therefore, circulating miRNAs can be present in
serum and other body fluids during the pathogenesis of
many disorders [1]. Circulating and whole blood miRNAs
(which contains cells that circulate throughout the body)
profiles are thus of particular interest as promising non-
invasive disease biomarkers [3, 5–8].
Over 700 miRNAs have been identified in the equine
genome with distinct subsets of miRNAs differentially
expressed in a tissue-specific manner [9, 10]. For example,
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horse specific miRNA in cartilage and bone have been
already reported [10] and the existence of hundreds of
horse specific transcripts may suggest the existence of
more horse specific miRNAs [11]. Due to their strong
sequence conservation, a majority of equine mature
miRNAs have been perfectly matched to human miRNAs
[4, 12]. The fact that many human miRNAs have been as-
sociated with human diseases indicates the potential of
investigating miRNA profiles in equine pathologic
conditions. However, the number of miRNAs studied
and annotated in the equine genome is still much
lower (n = 771) compared to human (n = 2,813) or
mouse (n = 2,045) genomes, according to miRBase v.21
[13]. Moreover, some miRNA may be expressed in a
breed-specific manner [14].
Current technology, i.e. small RNA sequencing
(sRNA-seq), is able to provide a comprehensive study to
determine the precise extend of miRNA profiles in
horse. Taking into account the specific biogenesis of
miRNA it is possible to distinguish short sequences that
may be derived from degraded mRNA and not from true
miRNA sequences [15]. The secondary structure of pre-
mature miRNA resembles a hairpin, which is then proc-
essed by the endonuclease Dicer to form miRNA du-
plexes. MiRNAs in either the 5’ or 3’ end of their
precursors are loaded into an RNA-induced silencing
complex, which yields functional miRNAs. The loop and
star sequences are usually degraded and therefore the
highest coverage of the reads is expected within the ma-
ture miRNA region [15].
In this study we used combined high-throughput se-
quencing and bioinformatics methods to identify equine
genome miRNAs. MiRNA profiles were thoroughly ana-
lysed by combining small RNA sequencing for multiple
tissues to search for novel equine circulating and tissue-
specific miRNAs. We prepared a total of 71 sRNA-seq
libraries from six solid tissues, blood and serum from
equine samples. Two different algorithms were applied
to support the authenticity of the identified miRNAs:
miRDeep2 [16] and the more stringent, miRdentify [17].
Given the miRNA’s fundamental role in transcriptional
and translational regulation in different pathologies, we
compared the expression profile of miRNA derived from
gluteus medius (GM) muscle of healthy horses and
horses affected with polysaccharide storage myopathy
type I (PSSM). We also hypothesized that the identifica-
tion of differences in the serum miRNA expression
profile between Warmbloods and ponies could reveal
unique biomarkers of equine breeds.
Results
Small RNA sequencing and mapping
We obtained small RNAs reads derived from 49 (HiSeq)
and 22 (SOLiD) libraries. SOLiD samples were prepared
from platysma, masseter and gluteus medius muscles,
heart, liver, cartilage, bone and blood of 35 horses.
MiRNA from the platysma and masseter muscles, heart
and liver were extracted from 15 healthy horses of differ-
ent ages and breeds (collected at the slaughterhouse).
The HiSeq samples included serum RNA samples from
44 Warmbloods horses and five ponies (four Shetland
and one Welsh pony). More details are given in Additional
file 1: Table S1.
After quality filtering for low quality reads and trim-
ming for adaptors sequences (see Methods for details),
HiSeq data from serum consisted of a total of 12 M
reads on average with mean per sequence quality of 38
in the Phred scale [18] per library. In these libraries, the
size distribution followed the RNA length distribution
reported in other equine and bovine serum samples
[19, 20], with the majority of the reads (78 %) falling
into piwi-interacting RNA region (30–32 nt) and with
a smaller peak (4 %) in the mature miRNA region
(22–23 nt). On the other hand, after removal of low-
quality reads, the flanking linker and primer se-
quences, SOLiD data comprised 8 M reads on average
with mean per sequence quality of 27 in the Phred scale
per library. The reads longer than 30 nt were filtered out
to exclude short fragments potentially derived from de-
graded cellular mRNA (see Methods) and finally the ma-
jority of the reads (77 %) were 21–23 nt long.
All remaining small RNAs from HiSeq and SOLiD
data (748 M sequencing reads; 11 M on average per
library) were aligned to the Equus caballus reference
genome (EquCab2; v2.74) with BowTie [21]. Overall,
91 % of reads were mapped, but 336 M (45 %) were fil-
tered out due to multiple mapping (more than 5 hits).
After collapsing reads that had identical sequence
(346 M tags; 46 %), 253,000 unique sequences were ob-
tained per library on average (Fig. 1). Only 0.39 % of
reads mapped to exonic regions of the protein-coding
genes (coding DNA sequences; CDSs), 38 % mapped to
5’ untranslated regions (UTR), and 18 % mapped to in-
trons (Fig. 2). The fraction of reads mapped to repeat el-
ements, rRNAs, tRNAs, other noncoding RNA and
repeated-related regions ranged from 12.7–93.4 %.
From 2.3 to 62.9 % (18.8 % on average) sequencing
reads per library mapped to the known miRNA genes in
agreement with the miRNA biogenesis [15]: most reads
mapped mature -3p and -5p sequences of the miRNAs
(Additional file 2: Figure S1).
Novel equine miRNA discovery
Two complementary algorithms were used to identify
miRNAs in equine tissues: i) miRDeep2; and ii) miR-
dentify. Briefly, we used equine known mature and
hairpin structure and human mature sequences as
guidance (miRBase v. 2); and minimum miRDeep
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score of 1 (−t Horse -b 1). Among 781 known equine
miRNAs expressed in our dataset (10 more mature
and hairpin combinations identified by mirDeep2 com-
pared to miRBase), from 131 to 256 were expressed per li-
brary (average = 183 (27 %)). The number of known
miRNAs per library identified by miRdentify ranged from
14 to 164 (average = 56). A total of 2,493 regions in
the equine genome expressed in the dataset met the
miRDeep2 criteria and thus were considered as novel
candidate miRNAs by miRDeep2, whereas only seven
met the criteria of miRdentify. More than half of the
novel miRNAs predicted by miRDeep2 (n = 1,319; 53 %)
and three miRNAs predicted by miRdentify were identi-
fied only in a single library and were thus filtered out
(Fig. 1). The remaining 1,174 novel miRNAs were scored
from 1 to 30,339 (mean = 35.6). The four novel miRNAs
identified by miRdentify partially overlapped with known
miRNAs: the ecaub_novel-miR-1175 was only two nucleo-
tides shorter than eca-mir-744, ecaub_novel-mir-1176
overlapped the position of an Ensembl predicted
ENSECAG00000025869, whereas the ecaub_novel-mir-
1177 was identified on the opposite strand of the eca-mir-
486, and ecaub_novel-mir-1778 was located in the region
of another Ensembl predicted ENSECAG00000026103.
None of the final set of the novel miRNAs identified by
miRdentify was simultaneously identified by miRDeep2.
The range of novel mature sequences length was 19–25 nt
with an average and median at 22 nt. An example of a
novel miRNA secondary structure with expression across
tissues is shown in Fig. 3.
When novel miRNAs were added to known miRNA
set, the number of clustered miRNA (defined as at least
Fig. 1 Workflow of the miRNA discovery analysis. The steps taken for the identification of 683 novel equine miRNAs from a total of 71
sRNA-seq libraries
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2 miRNAs within 3000 distance [22]) increased from 53
to 86, from which 15 could be identified among novel
miRNAs separately.
Equine miRNA expression
For the known and discovered putative miRNAs, we in-
vestigated their expression levels in the small RNA li-
braries. A total of 2,093 unique combination of mature
and hairpin sequences were expressed in our dataset
(one mature miRNA may derive from more than one
hairpin, also one or two mature miRNA derive from a
single hairpin structure [4]). The mean expression of
trimmed means of M values (TMM) of known (miRBase,
release 21) and novel miRNAs ranged from 0 to 140,700
count per million (cpm), with an average of 0.64 cpm
per miRNA. We then removed lowly expressed miRNAs
(<1 cpm in 90 % samples), as they seem to play minor
roles in gene expression regulation [23–25]. We detected
965 distinct mature miRNAs (280 known and 685 novel)
expressed from 951 unique hairpin sequences (268
known and 683 novel) by combining the results from
the two approaches. In total, there were 1,080 unique
combinations (mature miRNA expressed from hairpin)
with variable expression levels (0.20 to 140,700 cpm;
median = 1.96 cpm) in at least one small RNA library.
Among the 965 mature miRNAs, we observed that
miR-486 was the most abundant, together with a pu-
tative novel miRNA identified in the opposite strand
of miR-486, which was given here an identifier name
ecaub_miR_1177. These two miRNAs were highly
expressed in serum and blood samples compared to
other tissues (false discovery rate (FDR) = 1.05e-59
and 3.72e-60, respectively; Additional file 3: Table S2).
The highest number of novel miRNAs was identified
on chromosome 1 (n = 54) and only five novel
miRNA were identified on chromosome 27 (Fig. 4).
Among the 683 novel miRNAs, 334 (50 %) were tran-
scribed from the sense (+) strand of the DNA (Additional
file 4: Table S3). After removal of the lowly expressed
miRNAs, the length of the final set of novel mature
miRNAs ranged from 20 to 25 nt with median at
22 nt.
Tissue/breed specific miRNAs
MiRNAs expression patterns differ for specific tissues
differentiation states and health status. Multi-dimensional
scaling MDS showed that samples clustered according to
the tissue (Fig. 5), rather than by individual, thus prefigur-
ing a relevant scenario to draw tissue-specific miRNA
expression profiles [26].
MiRNAs expressed at moderate to high level (≥10 cpm)
in 90 % of libraries from the same tissue or breed (serum
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Fig. 2 Distribution of reads mapped within 10 kb up- and downstream of the gene coding regions. The percentage of reads per library mapped
to coding DNA sequences (CDS), 5’ and 3’ untranslated regions (UTR), introns, and within 1, 5, and 10 kb upstream of the transcription start site
(TSS) and downstream of the transcription end site regions of the coding genes is shown across all samples. Known miRNA genes were excluded
from this analysis
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samples) were considered as expressed in the particular
group (tissue/breed). From here on, we will refer to
miRNAs expressed in only one group as tissue/breed spe-
cific miRNAs. Subsequently, we further explored miRNAs
exhibiting differential expression between all muscle tis-
sues together, blood and serum together, liver, bone and
cartilage. The 562 miRNAs (317 novel mature miRNAs)
expressed at > 10 cpm on average in at least one tissue
presented different expression distribution: almost half of
the miRNAs were expressed only in one tissue (42 %;
44 % novel), 4 % (liver) to 11 % (muscles) were expressed
in a single tissue, and about 19 % in all the tissues:
muscles, liver, cartilage, bone, and circulating (serum or
blood) (Fig. 6a). The number of tissue-specific miRNAs
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Fig. 3 An example of novel miRNA structure and expression across tissues. The secondary structure of ecaub_novel-mir-74 predicted with
RNAfold in a graphical (a) and Vienna format (b). The mature miRNA sequence is indicated in red. Boxplots represent the expression levels of
ecaub_novel-miR-74 across the 10 tissues studied (c)
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discovered was similar and ranged from 23 (liver) to 63
(muscles) as shown in Fig. 6a.
Among muscles, the heart muscle had the highest
number of specific miRNAs (n = 58) (Fig. 6b). Only 108
miRNAs were expressed in all the tissues at the level
of > 10 cpm on average and among those only 14 were
novel miRNAs. The group specific miRNAs expressed at
>100 cpm on average are listed in Table 1. As depicted
in the Fig. 5, the MDS plot revealed miRNA expression
dissimilarity between healthy GM and PSSM GM. More
precisely, we identified five miRNAs expressed at the
level > 10 cpm solely in PSSM GM muscle: eca-miR-144,
eca-miR-20b, ecaub_novel-miR-472, ecaub_novel-miR-
568, and ecaub_novel-miR-892. The miR-144 was also
expressed at >10 cpm level in bone and eca-miR-20b in
bone and liver (Additional file 3: Table S2). However, none
of the miRNAs was significantly up- or down-regulated in
PSSM compared to healthy GM even at FDR < 0.1.
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Fig. 5 Multi-dimensional scaling plot of the RNA samples sequenced. The distances correspond to leading average (root-mean-square) of the
largest absolute log-fold-changes between each pair of samples [26]
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Close to one third (n = 69; 33 %) of the miRNAs
expressed in blood were also expressed in serum,
whereas 20 miRNAs could be detected only in serum
(Fig. 6c). Most of these serum-specific miRNAs were
expressed in both breeds (Warmbloods and ponies), al-
though we identified two miRNAs expressed solely in
Warmblood (eca-let-7f, eca-miR-361-5p) and 20 other
solely in ponies (Fig. 6d). Interestingly, among these
serum-specific miRNAs expressed solely in ponies was
eca-miR-483 that was expressed at >100 cpm on average
(Table 1, Additional file 3: Table S2).
Differentially expressed serum miRNAs
MiRNAs that showed strong specificity between Equus
caballus subspecies were determined by comparing the
expression between horse and pony serum. Age and sex
did not have effect on the miRNA expression profile,
with no significantly differentially expressed miRNAs
(DEmiRs), apart from one miRNA (eca-miR-8908j) that
passed the lower significance threshold usually suggested
for DEmiRs (upregulated in males with log 2 fold change
(log2FC) = 4.23; FDR = 0.013). The absorbance at 414 nm
had a significant effect on the expression of eca-miR-25
(FDR = 4.15e-4) and eca-miR-486-5p (FDR = 0.066) that
was previously reported as haemolysis dependant [27].
Fig. 6 Tissue and serum breed-specific mature miRNA. The venn diagrams show the number of known mature miRNAs (black) and novel miRNAs
(white) moderately or highly expressed (>10 cpm in 90 % group samples) in each condition: a tissue; b muscles; c circulating components;
d breed (serum)
Table 1 Tissue-specific miRNAs and their mean expression
Tissue Mature miRNA Mean expression [cpm]
Cartilage ecaub_novel-miR-174 127.47
Cartilage ecaub_novel-miR-27 117.53
Cartilage ecaub_novel-miR-634 106.9
Liver eca-miR-193 254.72
Serum Pony eca-miR-483 247.97
The table presents tissue-specific miRNAs among tissues evaluated in this
study with mean expression above 100 cpm
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We identified 50 differentially expressed (DE) miRNAs
(42 known and 9 novel) between pony and Warmblood
serum at a stringent significance threshold FDR < 0.001.
More than half of them (n = 35; 67 %) were upregulated in
ponies (range log2FC from 1.58 to 7.05), including 3 novel
miRNAs (Additional file 5: Table S4). The remaining 16
miRNAs were down-regulated (range log2FC from −1.31
to −6.04), including 6 novel miRNAs (Additional file 5:
Table S4). The most significant up- (eca-miR-122) and
down-regulated (eca-miR-328) miRNAs in ponies related
to Warmblood are shown on Fig. 7a-b.
We next selected a total of 177 target-genes of eca-
miR-122 using TargetScan [28] and performed gene set
enrichment analysis with GeneCodis [29] to assess their
biological role. The only significant Kyoto Encyclopedia
of Genes and Genomes (KEGG) pathway [30] was
glycolysis/gluconeogenesis (KEGG: 00010, corrected
hypergeometric p-value, Hyp* = 0.03), which encompassed
four target genes: pyruvate kinase, muscle (PKM2),
glucose-6-phosphatase, catalytic subunit (G6PC), dihydro-
lipoamide S-acetyltransferase (DLAT), and aldolase A,
fructose-bisphosphate (ALDOA).
The downregulated eca-miR-328 had 204 potential tar-
get genes reported by TargetScan and these genes sig-
nificantly enriched five KEGG pathways, from which the
most significant was the regulation of actin cytoskeleton
(KEGG: 04810, Hyp* = 0.01) with seven genes: fibroblast
growth factor 1 (FGF1) and 11 (FGF11), p21 protein
(Cdc42/Rac)-activated kinase 6 (PAK6), integrin alpha 5
(fibronectin receptor, alpha polypeptide) (ITGA5), v-rck
sarcoma virus CT10 oncogene homolog (avian) (CRK),
WAS protein family member 2 (WASF2), and FYVE,
RhoGEF and PH domain containing 1 (FGD1). The
other significant pathways were: pathways in cancer
(KEGG: 05200; Hyp* = 0.02); adherens junction (KEGG:
04520, Hyp* = 0.02); renal cell carcinoma (KEGG: 05211;
Hyp* = 0.03); and Wnt signalling pathway (KEGG:
04310; Hyp* = 0.04).
Discussion
Despite high sequence conservation much less is known
about equine miRNome compared to human or murine.
Therefore, in this study we examined the expression of
known and novel miRNAs in a comprehensive list of
nine horse tissues using 71 small RNA sequencing li-
braries derived from 83 horses. The identification of
novel miRNAs is limited by the fact that huge fraction
of small RNA-seq reads is filtered out due to multiple
mapping to the reference genome (n > 5 hits). These
short sequences with secondary structure (hairpin) are
often overlapping repeat regions [31].
As a gold standard has not been established in the
field of miRNA discovery, we decided to use two report-
edly well performing tools and combine the results.
While 1,174 miRNAs were identified in our study by
miRDeep2, only four were identified by the more strin-
gent miRdentify. The miRdentify does not use informa-
tion on other species miRNA annotations and usually
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results in lower number of miRNAs predicted [17].
Small overlap between those two tools is known and the
stringent ten parameters of miRdentify discards 50 % of
human annotated miRNAs [17]. Whereas all the four
miRNAs identified by miRdentify partially overlapped
the known or Ensembl predicted miRNA genes, novel
miRNAs identified by miRDeep2 often spanned unanno-
tated regions of the horse genome.
After removing lowly expressed miRNAs, our dataset
consisted of 683 novel miRNAs (Fig. 1), from which
49 % were transcribed from the sense strand, accordingly
to known equine miRNAs that are annotated equally on
both strands (miRBase, release 21). The highest number
of novel miRNAs was identified on the largest chromo-
some one, but also 40 novel miRNAs were identified on
unplaced chromosomes (Fig. 4). The unplaced chromo-
somes are often neglected, as it is the least annotated re-
gion of the horse genome. A future EquCab3 reference
genome is believed to decrease the number of unplaced
scaffolds and improve the quality of the reference gen-
ome. Interestingly, we identified a putative novel miRNA
encoded by the mitochondrial genome that has been
previously described in horse [32], however, the mitomiR
was identified only in one heart sample and was ex-
cluded from further analysis.
Our study aimed to identify tissue-/serum breed-
specific miRNAs and our definition of such miRNAs
presumed that specific miRNA can be expressed at low
level (<10 cpm) in other tissues but it has to be
expressed at least at the level of 10 cpm in 90 % of the
samples of a particular tissue/breed. This approach dif-
fers from other studies that were based on quantitative
reverse transcription PCR (RT-qPCR) or microarray
data, where “yes/no” approach was taken. However, we
hypothesize that since miRNAs can be exported and
transferred between the cells, they might appear in low
amounts in other tissues that they do not originate from
and where they are not directed to. Moreover, it has
been shown that only 200 miRNAs were expressed in
moderate to high levels (>10 cpm) in human brain
and most likely the moderately/highly expressed
miRNA play more important role in gene expression
regulation [23–25].
With our approach, we identified miRNAs that were
expressed in a tissue- and breed-specific manner
(Fig. 6a). We identified a group of 108 miRNAs that
were universally expressed at >10 cpm in 90 % of librar-
ies across all the tissues studied (Fig. 6a). Such a feature
identifies this group of miRNAs as a candidate universal
reference to normalize miRNA expression in normal
horse tissues. The expression pattern and tissues distri-
bution of these 108 miRNAs suggest that they might be
associated with biological fundamental functions in the
cell, such as metabolism. We identified 40 miRNAs that
were expressed in specific tissues with minimal or no ex-
pression in other tissues we examined, suggesting more
local function of these miRNAs that are not exported
outside the cell. For example, eca-miR-1 and eca-miR-
133a were highly expressed primarily in muscles and we
observed very little or no expression of these miRNAs
in other tissues. A total of eight serum-specific miRNAs
(eca-miR-1307, eca-miR-1379, eca-miR-7177b, eca-
miR-9021, ecaub_novel-miR-1145, ecaub_novel-miR-
262, ecaub_novel-miR-79, ecaub_novel-miR-932) were
expressed in a tissue-specific manner, although they
may derive from other tissues not analysed in the present
study and therefore have to be treated with caution.
The heart tissue had the most specific miRNAs among
all the muscles (Fig. 6b). The cardiac muscle is highly
specialized tissue and is a different type compared to
other skeletal muscles evaluated in this study and there-
fore more specific miRNAs were expected to be
expressed in the heart tissue [33]. Moreover, many
miRNAs have been already implicated in the cardiac de-
velopment and diseases [34, 35]. For such as limited
number of libraries per group examined, several miRNAs
that were previously considered as “tissue-specific” in
humans were not detected in our data. For instance, miR-
208, miR-302 (a-d), miR-367 were not detected (at
>10 cpm on average) in the heart tissue; miR-134 and
miR-208a were not detected in skeletal muscles; miR-483
in liver; or miR-483 and miR-377 in bone [36].
We also noticed that only less than half of the
miRNAs expressed in blood (33 %) were common with
serum miRNAs, suggesting that remaining 67 % of
miRNAs is expressed in blood cells and are not exported
to serum (Fig. 6c). However, we need to take into ac-
count that the serum miRNA set was derived from dif-
ferent horse breed and some additional breed specific
differences may apply as we shown for serum samples in
Fig. 6d.
Our study also provided an opportunity to re-visit and
confirm tissue-specific miRNAs previously reported in
horses. Interestingly only five novel cartilage/bone
miRNAs reported in [10] have been also identified in
this study, however, the mature miRNAs reported here
were slightly longer. Interestingly two of them were not
expressed (at >10 cpm level) in either cartilage or bone,
but in blood (Additional file 3: Table S2 and Additional
file 4: Table S3). From five most abundantly expressed
novel putative miRNA reported in equine plasma by Lee
et al. [37], only one miRNA was identified in our study
in bone and blood tissues with a mature sequenced
shorter by three nucleotides from 5’ end. From the 329
novel miRNAs reported by Kim et al. [9] only 11 had
exactly the same mature sequence as novel miRNAs re-
ported here. From the 896 putative novel miRNAs in-
cluded in the microarrays used by Mach et al. [32] only
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two had exactly the same mature sequence and further
24 had few nucleotides shorter mature sequence com-
pared to the miRNAs identified here (Additional file 4:
Table S3). One of the reasons of such discrepancy is the
different method used for putative novel miRNA identi-
fication in all of those studies. Moreover, a phenomenon
of multiple isoforms (isomiRs) derived from the same
precursor is known, where a pre-mature or mature se-
quence of a miRNA is modified by an addition, edition,
or subtraction of nucleotides [38, 39]. For single miRNA,
even a total of about 7000 isomiRs, including combina-
tions, can exist and consequently sRNA-seq can show/
generate a large part of these isomiRs [40].
Consistent with literature findings, miR-206 and miR-
133b were characterized solely in muscle, where they
promote differentiation or proliferation of myoblasts
[41]. In addition, non-muscle-specific miRNA involved
in myogenesis (e.g. miR-24, miR-181 and mir-214) were
broadly expressed [41]. Nonetheless, from the 166
tissue-specific known equine miRNAs reported in liver,
colon or muscles, a total of 132 were expressed in our
study and 105 of them were expressed at >10 cpm on
average in at least one group. Interestingly, 21 miRNAs
reported as tissue-specific in Kim et al. [9] were also
expressed in all groups studied here, at > 10 cpm on
average. From the 31 liver-specific miRNAs reported by
Kim et al. [9], only one was supported by our study with
our definition of tissue specificity (eca-miR-135a). On
contrary, four of liver-specific miRNAs reported here
were reported in Kim et al. [9] as muscle (eca-miR-299,
eca-miR-32, eca-miR-656) or colon-specific miRNAs
(eca-miR-429). It was not clear to us, how the authors
determined the tissue specificity and there is a clear
need to establish a common standard for future
reference.
Several recent studies have supported the possibilities
for the use of miRNA signatures as biomarkers for the
detection of cancer, pregnancy and other diseases such
as myopathies in humans and murine models. In our
study, the expression of miRNAs specific for PSSM-GM-
were not statistically differentially expressed relative to
healthy animals, which most likely was due to low num-
ber of samples and/or general low expression of these
specific miRNAs.
Because a significant genetic diversity (~10 %) and
structure between horse breeds has been described [42],
it is tempting to speculate that this genetic variability
may result in different miRNA synthesis and expression
that may contribute to phenotypic variation between
Warmblood and ponies. In fact, we identified 50
DEmiRs between Warmblood and pony serum samples
(Additional file 5: Table S4). The most significantly
DEmiR was eca-miR-122, which was highly up-regulated
in ponies compared to Warmbloods (Fig. 7a). This
miRNA, which is highly expressed in liver [43, 44], was
also expressed at the highest level in the liver samples
(mean = 43,681 cpm). The human miR-122 is involved in
glucose and lipid metabolism [45, 46] and it has been
proposed as a therapeutic target for metabolic diseases
[46]. Ponies are known to be among breeds more prone
to develop equine metabolic syndrome (EMS) [47] and
therefore miR-122 may be of particular interest for un-
ravelling the molecular mechanism of this disease.
Moreover, the pony serum specific miR-483, also signifi-
cantly upregulated in ponies (FDR = 4.15e-8), has been
shown to be upregulated in patients with adrenocortical
cancer [48, 49]. This may suggest that eca-miR-483
might potentially increase the predisposition to meta-
bolic diseases in ponies.
Moreover, it was reported that high mobility group
AT-hook 2 gene (HMGA2) carries a SNP associated with
height in Shetland Pony [50]. HMGA2 also down-
regulates the expression of miR-200b [51]. Both miR-
200a and miR-200b were significantly upregulated in
pony serum in our study with log2FC >3.5 (Fig. 7c,
Additional file 3: Table S2). Therefore, we can speculate
that impaired HMGA2 has decreased capability to in-
hibit the miR-200 expression in ponies.
To confirm the breed specificity of the serum miRNAs
more serum samples from various horse breeds are ne-
cessary to analyse in terms of their miRNA profile in fu-
ture. However, this study shows clear differences in
miRNA profiles between ponies and Warmbloods.
Conclusions
Our sRNA-seq data and analyses of expression patterns
in 9 different tissues presented a global view of tissue
distribution of known and novel miRNAs and the rela-
tion to their chromosomal locations. We identified 683
novel equine miRNAs expressed in seven solid tissues,
blood and serum. Additionally, our approach evidenced
that such data supported identification of specific
miRNAs as markers of functions related to breeds or
disease tissues. For instance, we showed an increased ex-
pression of circulating serum miR-122 and miR-200 in
ponies together with the predicted miRNA target genes
that are required in the control of energy metabolism.
The increased expression of eca-miR-483 in ponies rela-
tive to Warmblood suggested an increased predispos-
ition to metabolic diseases in ponies. Lastly, we were
also able to identify miRNAs not exported to the serum,
which most likely have local function.
Methods
Samples, RNA extraction and RNA-seq
The SOLiD libraries were prepared from gluteus medius,
platysma, masseter, heart (exterior cardiac muscle), car-
tilage, liver, bone, and blood samples derived from a
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total of 35 horses of different age and breed (collected at
the slaughterhouse). Two SOLID libraries were prepared
from two blood samples collected from one endurance
horse of Arabian breed aged of 10 years-old before and
after 2 h of training exercise at canter, respectively. Nine
SOLiD libraries were prepared from cartilage and sub-
chondral bone explants collected in the middle trochlea
of healthy stifle joint from four 6 months old Anglo-
Arabian horses [10]. Two cartilage libraries were pre-
pared from the same set of three horses, however, de-
rived from a different sample collection. The bone
library also consist of pooled RNA samples derived from
three horses. The SOLiD libraries prepared from gluteus
medius, platysma, masseter, heart and liver were derived
from 30 horses (12.5 ± 5.6 yo), pooled by three animals
of different breeds 15 Cob Normand, 8 French trotter, 6
Selle Français, and 1 Trait du Nord. More details on the
samples can be found in Additional file 1: Table S1. Dif-
ferent types of muscles were chosen to better under-
stand their roles in the regulation of physiological
processes and metabolism in skeletal muscles. While
masseter contains a type I slow oxidative fiber muscle,
platysma is enriched in type IIX fast glycolytic fiber
muscle and gluteus medius predominantly contains type
IIB fast glycolytic fiber. On the other hand, heart is
highly resistant to fatigue because its high content of
mitochondria, which enables continuous aerobic respir-
ation via oxidative phosphorylation. After collection in
the slaughterhouse, 60 mg of tissue samples were cut
in small pieces and lysed in 1 ml of Trizol reagent
(Invitrogen, Cergy Pontoise, France) with ceramic
beads (Bertin technologies, St Quentin en Yvelines,
France). Epiphyseal cartilage and subchondral bone
were obtained from healthy stifle joint (macroscopical
examination at necropsy). Whole blood was sampled
from one Arabian horse before the 160 km ride and
then again afterwards.
The mirVana™ miRNA Isolation Kit (Ambion, Life
Technologies) was used to extract in parallel Total RNA
and small RNA (smRNA) from tissues following the
manufacturer’s protocol, whereas total blood RNA was
isolated using a PAXgene Blood RNA Kit (Qiagen),
according to the manufacturer’s instructions. Total
RNA was purified using RNeasy Mini Kit (Qiagen,
Courtaboeuf, France) according to the manufacturer's
recommendations. Residual genomic DNA was re-
moved using DNase digestion with RNase-free DNase I
Amp Grade (Invitrogen, Cergy Pontoise, France) following
the recommended protocol. RNA concentration was
measured by using a NanoDrop spectrophotometer
(NanoDrop Technologies, Wilmington, USA), and the
RNA integrity value (RIN) was assessed by using a
2100 Bioanalyzer (Agilent Technologies Inc., Santa-
Clara, USA). All samples had an RNA integrity number
(RIN) > 8. For further details on SOLiD samples, prepar-
ation and sequencing, see [10, 32].
A total of 22 libraries were prepared: five for gluteus
medius muscle; three for heart, liver, masseter, and pla-
tysma muscle; two for cartilage and blood, and one for
bone. Among the five libraries prepared from gluteus
medius muscle, two were prepared from healthy muscle,
three from horses affected by polysaccharide storage my-
opathy, type I, PSSM. The PSSM-affected horses were
diagnosed based on GYS2 genotype and histological
examination of glycogen digestion as described in [52, 53].
Within each library, three different horses were
pooled to decrease the effect of the individual vari-
ability, except for the blood samples where each li-
brary comes from the same animal (Additional file 1:
Table S1) but the samples come from different
physiological moments (before and after exercise [32].
Approximately 200 ng of mRNA extracted from the
different tissues and blood were used for library con-
struction following the protocol for the SOLiD Total
RNA-Seq Kit (Applied Biosystems, Life Technologies).
Libraries were sequenced with 50 cycles on 5500XL
Series Genetic Analysis System at the Metaquant core
facility (INRA, Jouy-en-Josas, France).
The serum samples were collected from 31 Swiss and
13 other European Warmblood horses (22 males and 22
females, aged 6–32 years, average = 18 years), and four
Shetland and one Welsh pony (three males and two fe-
males, aged 5–19 years, average = 12 years). Briefly,
blood was collected from jugular vein into sodium-
heparin-containing vacutainers [54]. Within 1–6 h
serum was separated from cells via centrifugation 1800 g
for 20 min. Serum was then transferred to new tubes
and stored in −80 °C until RNA extraction (up to
4 years). In order to verify the level of haemolysis in
serum samples we used VersaMax ELISA Microplate
Reader (Molecular Devices) and SoftMax Pro software
(version 3.1.2). The absorbance in 200 μl of serum
was measured at 414 nm wavelength, which is the
length of maximum absorbance for haemoglobin [55, 56].
The RNA was extracted from 2 ml of serum using
miRNeasy serum/plasma kit as described in [20]. The
concentration of RNA extracted was measured with
Qubit RNA High Sensitivity kit and ranged from 2 to
428 ng/μl (20 ng/μl on average). Twelve samples were
randomly chosen for the small RNA length distribu-
tion assay with Bioanalyzer 2100 small RNA chip.
The miRNA in small RNA content of these 12 sam-
ples ranged from 69 to 89 % (81 % on average). The
RNA was successfully converted into single-end li-
braries with NEBNext Multiplex Small RNA Library
Prep Set for Illumina (New England BioLabs) and se-
quenced on an Illumina HiSeq 2500 with 50 sequen-
cing cycles.
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Data pre-processing
The raw sequencing reads from each library were check
for quality with FASTQC v. 0.11.2 [57]. The sequencing
data was processed in the following manner: 1) multiple
adapter sequences were trimmed with cutadapt (v. 1.8)
with the following options: -c -a ‘adapter sequence’ -m
18 -M 30 –trim-n -q 15,10 [58] for SOLiD data; or
–trim-n -b ‘sample specific adapter sequence’ -m 15 for
HiSeq data; 2) trimmed reads were mapped to the Equus
caballus reference genome EquCab2 v2.74 [59] with
BowTie (v. 0.12.9) [21] with the following options: -n
1 -l 8 -a -m 5 –best –strata (for colour-space SOLiD
reads additional options were used: -c –col-keepends).
We required small RNAs to map with one base mis-
matches as recommended in [60]. Reads mapping
more than five times to the genome were discarded.
The mapping quality and read distribution was ana-
lysed with RSeQC (v. 2.6.1) [61]. We inspected the
read distribution among: i) known equine genes without
miRNA genes (Ensembl, release 81); ii) known equine
miRNA genes; iii) repeating elements annotated in horse
genome (based on RepeatMasker [62, 63]). Known equine
and human miRNA mature and hairpin sequences were
downloaded from miRBase, release 21 [64].
The pre-processed mapped reads in BAM format were
deposited at the European Nucleotide Archive (http://
www.ebi.ac.uk/ena/data/view/PRJEB14485).
miRNA discovery
We used two different tools for miRNA discovery: (i)
miRDeep2 (v. 0.0.7) [15, 16] and (ii) miRdentify (v. 1.0),
which is high stringency predictor [17]. The miRNA
identification analysis was performed independently in
each sample to allow for authentic detection of miRNAs.
The high-quality sequencing reads were used as input
data. Briefly, the miRDeep2 algorithm excises the sRNA
sequence and computes their secondary RNA structure
with RNAfold [65] to predict miRNA precursors that are
later scored for their likelihood [15]. A total miRDeep2
score was designated based on an algorithm incorporat-
ing the statistics of read positions, read frequencies
within stem-loops, and posterior probability that the
stem-loop was derived from an authentic miRNA. To
prevent false positive detection of miRNA stem-loops,
the signal-to-noise ratios estimated over 100 rounds of
independent permutations were calculated for different
miRDeep log-odds score cut-offs from −10 to 10. For a
prediction of potential horse specific RNAs, a criterion
of miRDeep score of 1 was adopted as a cut-off point.
Therefore, all precursors with total miRDeep scores
above the cut-off point were considered as putative
miRNAs. The miRDeep2 tool allows for guided search
for novel miRNA with an optional set of miRNAs from
a related species. As the miRNA annotations in horse
genome are relatively poor, we used the most compre-
hensive set of human miRNAs as guidance. Known
equine miRNAs were obtained from the miRBase
database, release 21 [13]. In addition, human known
miRNAs from miRBase were used as “related species”
set of miRNAs. The putative miRNA identified by the
miRDeep2 program or miRdentify that did not show a
significant match to miRBase were regarded as novel
miRNAs. The miRdentify tool applies 10 additional pa-
rameters: heterogeneity at both 5’ and 3’ ends (low het-
erogeneity is expected), 5’ and 3’ arm overhang (two
nucleotide 3’ overhangs at both ends), duplex and flank-
ing sequence minimal free energy (MFE; lower MFE is
desirable), nucleotide and structural entropy (higher
degree of nucleotide entropy and lower structural
complexity of the hairpin are desirable), tailing (high
level of tailing with adenosine or uridine); and multi-
map factors (reads with more than four genomic hits
are discarded) [17].
The miRNAs were identified for each sample separ-
ately. MiRNA that differed only by additional two nucle-
otides at the start/end position were considered as a
single miRNA and the miRNA that was identified in the
highest number of samples or had a higher miRDeep2
score was chosen as a representative and most likely true
miRNA. Novel miRNA identified in one sample only
were filtered out.
We then combined the novel and known miRNA and
the miRNA expression for each sample was determined
with miRDeep2 quantifier tool [16]. Mature miRNAs
expressed at < 1 cpm in 90 % of samples were filtered
out. Then, miRNAs expressed at ≥ 10 cpm in 90 % of
group samples were considered as expressed in the
group analysed (tissue/breed). To analyse whether
miRNAs were ubiquitously expressed among the tar-
geted tissues, a Venn diagram was plotted by using
“venn.diagram” function from VennDiagram R package.
Differential expression analysis of serum samples
The MDS plots, which measure the differences be-
tween samples and project it into two dimensions,
were through the “MDSplot” function of edgeR pack-
age. The estimated raw counts of each miRNA from
miRDeep2 output were used for the differential ex-
pression analysis using edgeR package. To avoid in-
clusion of miRNAs containing too few reads, as
recommended by authors of the package, only mature
miRNAs with the expression > 10 cpm in 90 % of the
samples were kept for the analysis. In order to dis-
cover biologically important changes in expression,
the TMM normalization method [66] of edgeR pack-
age was applied (“calcNormFactors” function) and the
dispersions were calculated based on the quantile-ad-
justed conditional maximum likelihood (“estimateDisp”
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function). The differentially expressed (DE) genes were de-
tected by applying an exact test [67]. The edgeR generated
a fold change for each miRNA, P-values and the associ-
ated Benjamin-Hochberg false discovery rate (FDR)
values. MiRNAs showing a FDR < 0.001 were considered
as DE.
Biological interpretation of the analysis
The potential targets of tissue and serum breed-specific
miRNAs were identified using TargetScan (release 6.2)
[28] and subjected for gene set enrichment analysis with
GeneCodis [29] to infer the main biological functions as-
sociated the different tissues. We used KEGG pathways
annotated for human, as equine annotations were not
available.
Additional files
Additional file 1: Table S1. RNA sample description. An Excel table
with details on RNA samples used for library preparation. For each library
horse ID, tissue, breed, age, sex, and absorbance at 414 nm (only serum
samples) are given. (XLSX 17 kb)
Additional file 2: Figure S1. miRNA gene body coverage. The read
coverage of known miRNAs genes per library. On the Y axis coverage
measured by Pearson’s skewness coefficients. All transcripts were scaled
into 100 nt and the length is denoted on the X axis (RSeQC v.2.6.1).
(PDF 33 kb)
Additional file 3: Table S2. Known and novel miRNAs expression
values. An Excel table with normalized count per million values (cpm) for
each of the known and novel miRNAs expressed at > 1 cpm in 90 % of
samples. (XLSX 519 kb)
Additional file 4: Table S3. Novel miRNA characteristics. An Excel table
with novel miRNAs identified in this study. Mature miRNA sequences,
genomic coordinates of the hairpins, strand and miRDeep2 score are
given. (XLSX 85 kb)
Additional file 5: Table S4. Differentially expressed miRNAs in pony
serum compare to Warmbloods. An Excel table with log 2 fold changes
and false discovery rates of genes significantly differentially expressed in
serum derived from 4 Shetland and one Welsh pony in comparison to 44
Warmbloods. (XLSX 11 kb)
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